Inicio49BA • FRA
add
BeOne Medicines AG
Cierre anterior
302,00 €
Intervalo diario
302,00 € - 308,00 €
Intervalo anual
166,00 € - 322,00 €
Cap. bursátil
344,95 mil M HKD
Volumen medio
5,00
Relación precio-beneficio
-
Rentabilidad por dividendo
-
En las noticias
Investing.com
hace 13 horas
BeOne Medicines stock price target raised to $408 from $395 at RBC Capital
2,03 %
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos | 1412,28 M | 41,00 % |
Gastos operativos | 1052,66 M | 10,64 % |
Ingresos netos | 124,84 M | 202,88 % |
Margen de beneficio neto | 8,84 | 172,94 % |
Beneficios por acción | 1,09 | 267,89 % |
EBITDA | 198,86 M | 496,46 % |
Tipo impositivo efectivo | 15,17 % | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 4036,87 M | 48,74 % |
Activos totales | 7632,59 M | 31,04 % |
Responsabilidades totales | 3503,26 M | 47,29 % |
Patrimonio total | 4129,33 M | — |
Acciones en circulación | 110,66 M | — |
Precio-valor contable | 8,09 | — |
Rentabilidad económica | 5,85 % | — |
Retorno sobre capital | 8,20 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos netos | 124,84 M | 202,88 % |
Efectivo de operaciones | 402,55 M | 113,70 % |
Efectivo de inversión | -49,27 M | 63,20 % |
Efectivo de financiación | 961,27 M | 7.491,79 % |
Variación neta del flujo de caja | 1324,46 M | 1.286,91 % |
Flujo de caja libre | 306,27 M | 120,68 % |
Información sobre la empresa
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Director ejecutivo
Fundación
28 oct 2010
Sitio web
Empleados
11.000
